DE69720719T2 - Mesylat des trihydrats des 5-(2-(4-(1,2-benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist - Google Patents

Mesylat des trihydrats des 5-(2-(4-(1,2-benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist

Info

Publication number
DE69720719T2
DE69720719T2 DE69720719T DE69720719T DE69720719T2 DE 69720719 T2 DE69720719 T2 DE 69720719T2 DE 69720719 T DE69720719 T DE 69720719T DE 69720719 T DE69720719 T DE 69720719T DE 69720719 T2 DE69720719 T2 DE 69720719T2
Authority
DE
Germany
Prior art keywords
ziprasidon
benzothiazol
ons
trihydrate
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69720719T
Other languages
English (en)
Other versions
DE69720719D1 (de
Inventor
R Busch
A Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE69720719D1 publication Critical patent/DE69720719D1/de
Application granted granted Critical
Publication of DE69720719T2 publication Critical patent/DE69720719T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69720719T 1996-05-07 1997-03-26 Mesylat des trihydrats des 5-(2-(4-(1,2-benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist Expired - Lifetime DE69720719T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07
PCT/IB1997/000306 WO1997042190A1 (en) 1996-05-07 1997-03-26 Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist

Publications (2)

Publication Number Publication Date
DE69720719D1 DE69720719D1 (de) 2003-05-15
DE69720719T2 true DE69720719T2 (de) 2003-11-06

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69720719T Expired - Lifetime DE69720719T2 (de) 1996-05-07 1997-03-26 Mesylat des trihydrats des 5-(2-(4-(1,2-benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist

Country Status (46)

Country Link
US (1) US6110918A (de)
EP (1) EP0904273B1 (de)
JP (1) JP3102896B2 (de)
KR (1) KR100333214B1 (de)
CN (1) CN1092658C (de)
AP (1) AP838A (de)
AR (1) AR007003A1 (de)
AT (1) ATE236902T1 (de)
AU (1) AU730856C (de)
BG (1) BG63601B1 (de)
BR (1) BR9708932A (de)
CA (1) CA2252895C (de)
CO (1) CO4940465A1 (de)
CZ (1) CZ289216B6 (de)
DE (1) DE69720719T2 (de)
DK (1) DK0904273T3 (de)
DZ (1) DZ2221A1 (de)
EA (1) EA001180B1 (de)
EG (1) EG24401A (de)
ES (1) ES2192264T3 (de)
GT (1) GT199700042A (de)
HK (1) HK1017893A1 (de)
HN (1) HN1997000040A (de)
HR (1) HRP970235B1 (de)
HU (1) HU229057B1 (de)
ID (1) ID17504A (de)
IL (1) IL126590A (de)
IS (1) IS2301B (de)
MA (1) MA26427A1 (de)
ME (1) ME00901B (de)
MY (1) MY128051A (de)
NO (1) NO312513B1 (de)
NZ (2) NZ508303A (de)
OA (1) OA10908A (de)
PL (1) PL188164B1 (de)
PT (1) PT904273E (de)
SI (1) SI0904273T1 (de)
SK (1) SK282674B6 (de)
TN (1) TNSN97073A1 (de)
TR (1) TR199802241T2 (de)
TW (1) TW427989B (de)
UA (1) UA47467C2 (de)
UY (1) UY24543A1 (de)
WO (1) WO1997042190A1 (de)
YU (1) YU49398B (de)
ZA (1) ZA973875B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
PT985414E (pt) * 1998-05-26 2004-01-30 Pfizer Prod Inc Metodo de tratamento de glaucoma e retinopatia isquemica
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EP1738749A1 (de) 1999-12-23 2007-01-03 Pfizer Products Inc. Arzneizusammensetzung mit erhöhter arzneistoffkonzentration
JP2003534381A (ja) * 2000-06-02 2003-11-18 ファイザー・プロダクツ・インク 精神障害及び眼障害の治療用ｓ−メチル−ジヒドロ−ジプラシドン
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
CA2525323A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
MXPA05012392A (es) * 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamientos de ansiedad con ziprasidona.
WO2004100954A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
CA2528100A1 (en) * 2003-06-03 2005-04-21 Teva Pharmaceutical Industries Ltd Polymorphic forms of ziprasidone hcl and processes for their preparation
WO2005020929A2 (en) * 2003-09-02 2005-03-10 Imran Ahmed Sustained release dosage forms of ziprasidone
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
EP1592688A2 (de) * 2003-12-18 2005-11-09 Teva Pharmaceutical Industries Ltd. Polymorphe form b2 von ziprasidonbase
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
EP1720867B1 (de) * 2004-02-27 2009-12-09 Ranbaxy Laboratories Limited Verfahren zur herstellung von ziprasidon
WO2006026426A2 (en) * 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
CN101106972A (zh) * 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
US20080286373A1 (en) * 2007-05-18 2008-11-20 Palepu Nageswara R Ziprasidone formulations
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
UY24543A1 (es) 2000-09-29
JPH11509865A (ja) 1999-08-31
PL188164B1 (pl) 2004-12-31
SI0904273T1 (en) 2003-08-31
CZ349498A3 (cs) 1999-09-15
NZ508303A (en) 2001-07-27
OA10908A (en) 2001-10-26
TNSN97073A1 (fr) 2005-03-15
IS2301B (is) 2007-10-15
ATE236902T1 (de) 2003-04-15
CZ289216B6 (cs) 2001-12-12
ZA973875B (en) 1998-11-06
PL329880A1 (en) 1999-04-12
DZ2221A1 (fr) 2002-12-03
CN1216990A (zh) 1999-05-19
IL126590A0 (en) 1999-08-17
AP9700978A0 (en) 1997-07-31
BG63601B1 (bg) 2002-06-28
BG102893A (en) 1999-09-30
GT199700042A (es) 1998-10-02
TW427989B (en) 2001-04-01
HUP9902808A3 (en) 2000-04-28
EA001180B1 (ru) 2000-10-30
EP0904273B1 (de) 2003-04-09
DE69720719D1 (de) 2003-05-15
CN1092658C (zh) 2002-10-16
EP0904273A1 (de) 1999-03-31
MA26427A1 (fr) 2004-12-20
HUP9902808A2 (hu) 2000-03-28
CA2252895A1 (en) 1997-11-13
DK0904273T3 (da) 2003-07-07
NZ332219A (en) 2005-02-25
CO4940465A1 (es) 2000-07-24
EA199800909A1 (ru) 1999-04-29
HN1997000040A (es) 1997-06-05
AU1936897A (en) 1997-11-26
ES2192264T3 (es) 2003-10-01
IL126590A (en) 2001-11-25
MY128051A (en) 2007-01-31
US6110918A (en) 2000-08-29
NO985193L (no) 1998-11-06
EG24401A (en) 2009-04-29
ID17504A (id) 1998-01-08
SK150598A3 (en) 2000-03-13
AU730856C (en) 2001-11-15
TR199802241T2 (de) 1999-02-22
NO985193D0 (no) 1998-11-06
PT904273E (pt) 2003-06-30
KR20000010822A (ko) 2000-02-25
CA2252895C (en) 2002-08-20
ME00901B (me) 2005-11-28
AR007003A1 (es) 1999-10-13
YU49398B (sh) 2005-11-28
YU17397A (sh) 2000-10-30
HK1017893A1 (en) 1999-12-03
HU229057B1 (en) 2013-07-29
HRP970235B1 (en) 2002-08-31
UA47467C2 (uk) 2002-07-15
AU730856B2 (en) 2001-03-15
WO1997042190A1 (en) 1997-11-13
JP3102896B2 (ja) 2000-10-23
IS4878A (is) 1998-10-23
BR9708932A (pt) 1999-08-03
NO312513B1 (no) 2002-05-21
HRP970235A2 (en) 1998-06-30
AP838A (en) 2000-05-03
KR100333214B1 (ko) 2002-06-20
SK282674B6 (sk) 2002-11-06

Similar Documents

Publication Publication Date Title
DE69720719T2 (de) Mesylat des trihydrats des 5-(2-(4-(1,2-benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist
DE69731094D1 (de) MESYLATDIHYDRATSALZE von 5-(2-(4-(1,2-BENZISOTHIAZOL-3-yl)-1-PIPERAZINYL)-ETHYL)-6-CHLORO-1,3-DIHYDRO-2(1H)-INDOL-2-ON (=ZIPRASIDONE), DESSEN HERSTELLUNG UND VERWENDUNG ALS DOPAMIN-D2-ANTAGONIST
NO933093D0 (no) Monohydrat av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2h-indol-2-on hydroklorid
DK0922701T3 (da) Fremgangsmåde til fremstilling af N-(4-fluorphenyl)-N-(1-methylethyl)-2-[(5-(trifluormethyl)-1,3,4-thiadiazol-2-yl)-oxy]acetamid
HUP9902404A3 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-choloro-1,3-dihydro-2(2h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
SI1556378T1 (sl) Acilni derivati 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperaznil)etil)-6-kloro-1,3-dihidro -2H-indol-2-ona z nevrolepticno aktivnostjo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition